WHO ICTRP trial
Prospective study of cladribine combined with low-dose cytarabine in the…
ChiCTR1900026266 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR1900026266 |
|---|---|
| Public title | Prospective study of cladribine combined with low-dose cytarabine in the treatment of higher-risk myelodysplastic syndrome patients refractory or relapsed after hypomethylation agents |
| Scientific title | Prospective study on the efficacy and safety of cladribine combined with low-dose cytarabine in the treatment of patients with higher-risk myelodysplastic syndrome refractory or relapsed after hypomethylation agents |
| Primary sponsor | Shanghai Jiaotong University Affiliated Sixth People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 4 |
| Countries | China |
| Conditions | myelodysplastic syndrome |
| Interventions | 1:Cladribine combined with cytarabine |
| Registration date | Sep 28, 2019 |
| Target size | 1:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: